Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christella Guzman

Nurse Practitioner, Adult Health Honolulu, HI Nurse Practitioner

NPI 1851480701 CMS profile 10660142

550 S Beretania St, Ste 702, Honolulu, HI 96813

Open in the dashboard

General payments

$7,601

250 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christella Guzman of Honolulu, HI is reported in the CMS Open Payments database as having received $7,601 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $494 16
2024 General $1,121 18
2023 General $1,230 54
2022 General $2,906 74
2021 General $1,849 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christella Guzman
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Christella Guzman were reported at $494. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Christella Guzman Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,849 $138 $43–$438 $132
2022 $2,906 $165 $54–$494 $149
2023 $1,230 $178 $61–$549 $160
2024 $1,121 $186 $62–$575 $164
2025 $494 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Edwards Lifesciences Corporation $1,788 12 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $839 31 payments
  3. Novartis Pharmaceuticals Corporation $785 48 payments
  4. Janssen Pharmaceuticals, Inc $580 35 payments
  5. AstraZeneca Pharmaceuticals LP $553 26 payments
  6. Amgen Inc. $553 21 payments
  7. Abiomed $461 7 payments
  8. Novo Nordisk Inc $275 9 payments
  9. Merck Sharp & Dohme Corporation $262 12 payments
  10. E.R. Squibb & Sons, L.L.C. $215 12 payments
  11. Other $1,291 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,410 244 payments
  2. Travel and Lodging $1,144 3 payments
  3. Education $47 3 payments
Products named General payments · program years 2021–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $900 7 payments
  2. JARDIANCE Diabetes $638 26 payments
  3. XARELTO $580 35 payments
  4. ENTRESTO $539 38 payments
  5. Impella $440 6 payments
  6. Repatha $384 17 payments
  7. BRILINTA $377 21 payments
  8. VERQUVO $262 12 payments
  9. LEQVIO $246 10 payments
  10. JARDIANCE Diabetes $201 5 payments
  11. Other $3,052 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

503

Median for Nurse Practitioner: 389

Drug cost

$218,979

Median for Nurse Practitioner: $21,885

Branded share of claims

48.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 34 $54,027
Eliquis Apixaban Brand 32 $50,982
Entresto Sacubitril/Valsartan Brand 24 $39,231
Brilinta Ticagrelor Brand 29 $26,912
Xarelto Rivaroxaban Brand 17 $26,059
Vascepa Icosapent Ethyl Brand 13 $13,403
Atorvastatin Calcium Generic 53 $1,925
Clopidogrel Clopidogrel Bisulfate Brand 65 $1,663
Metoprolol Succinate Generic 64 $1,309
Ranolazine Er Ranolazine Brand 11 $1,141

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$7,998

Medicare's payments for the services billed

Medicare patients

72

Average age 75

Services billed

97

23 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Chronic kidney disease 58%
Heart failure 54%
Diabetes 51%
Atrial fibrillation 35%
Arthritis 24%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $165
$165 34 —
Wegovy
  • Novo Nordisk Inc $135
$135 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $33
$33 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $23
$23 32 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record